# A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

> **NCT00619099** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 67 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** decitabine
- **DRUG:** decitabine

## Key facts

- **NCT ID:** NCT00619099
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2012-03
- **Final completion:** —
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2013-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00619099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00619099, "A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00619099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*